Decibel Therapeutics to Present at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting
10 Maio 2023 - 5:30PM
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology
company dedicated to discovering and developing transformative
treatments to restore and improve hearing and balance, today
announced that it will present at the American Society of Gene and
Cell Therapy (ASGCT) 25th Annual Meeting, being held in Los
Angeles, California May 16 – 20th, 2023.
The Company will deliver podium
presentations on its lead gene therapy product candidate, DB-OTO, a
gene therapy designed to provide hearing to individuals with
hearing loss caused by mutations of the otoferlin gene, and its
AAV.103 product candidate, a gene therapy designed to restore
hearing in individuals with hearing loss caused by mutations of the
gap junction beta-2 (GJB2) gene. Decibel will also present posters
related to its preclinical pipeline and its platform.
Podium Presentations
Nonclinical Pharmacology,
Biodistribution, and Safety Studies Supporting the Clinical
Development of DB-OTO (AAV1-Myo15-hOTOFv5) for Hearing Loss Due to
Genetic Otoferlin Protein DeficiencyPresenter: Vassili
Valayannopoulos, M.D., Ph.D., MBA Session Title:
Pharmacology/Toxicology Studies: Bio Distribution Date & Time:
Friday, May 19, 5:15 – 5:30 p.m. PTLocation: Petree Hall C
Precise Targeting of GJB2
Cells Results in Safe and Efficacious Gene Therapy in a Rodent
Model of Hearing Loss Due to GJB2 DeficiencyPresenter:
Gabriela Pregernig, Ph.D.Session Title: Ophthalmic and Auditory
Diseases Date & Time: Saturday, May 20, 9:15 – 9:30 a.m.
PTLocation: Room 502 AB
Poster Presentations
Development of a Platform for
Parallel Functional Evaluation of Cell Type Specific Synthetic
Promoters for Gene Therapy Poster Board Number: 432Date
& Time: Wednesday, May 17, 12:00 – 2:00 p.m. PT
Restoration of Auditory
Function with Otoferlin Gene Transfer Therapy in Nonsense (Q828X)
and Missense (pR1934Q and Deaf5) Models of OTOF
DeficiencyPoster Board Number: 1115Date & Time:
Thursday, May 18, 12:00 – 2:00 p.m. PT
Rescue of Hearing Loss in a
STRC KO Mouse Using Multiple Dual Vector Gene Therapy
StrategiesPoster Board Number: 1533Date & Time:
Friday, May 18, 12:00 – 2:00 p.m. PT
About Decibel TherapeuticsDecibel Therapeutics
is a clinical-stage biotechnology company dedicated to discovering
and developing transformative treatments to restore and improve
hearing and balance, one of the largest areas of unmet need in
medicine. Decibel has built a proprietary platform that integrates
single-cell genomics and bioinformatic analyses, precision gene
therapy technologies and expertise in inner ear biology. Decibel is
leveraging its platform to advance gene therapies designed to
selectively replace genes for the treatment of congenital,
monogenic hearing loss and to regenerate inner ear hair cells for
the treatment of acquired hearing and balance disorders. Decibel’s
pipeline, including its lead gene therapy product candidate,
DB-OTO, to treat congenital, monogenic hearing loss, is designed to
deliver on our vision of creating a world of connection for people
with hearing and balance disorders. For more information about
Decibel Therapeutics, please visit www.decibeltx.com or follow us
on Twitter.
Investor Contact:Julie SeidelStern IR,
Inc.212-362-1200Julie.seidel@sternir.com
Media Contact:Chris RaileyTen Bridge
Communications617-834-0936chris@tenbridgecommunications.com
Decibel Therapeutics (NASDAQ:DBTX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Decibel Therapeutics (NASDAQ:DBTX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024